The purpose of the Training Program in Transfusion Medicine and Hematology is to provide research training for post-doctoral fellows (MD only, MD-PhD and PhD's) in the scientific disciplines related to Transfusion Medicine and Hematology. Upon completion of this 2-year program, each trainee will be qualified to assume an academic position and conduct an independent program of clinical or laboratory investigation in one or more of the fields of study included in this program, including Transfusion Medicine and Immunohematology (Track I); Hemoglobinopathies, Hematopoiesis and Cell Therapy (Track II); Coagulation and Thrombosis (Track III); and Molecular Biology, Molecular Signaling, and Genetics (Track IV). In each of these tracks, exposure to the clinical aspects of the area selected (comprising less than 25 per cent of total trainee time during the tenure of this fellowship) will be provided to permit the trainee to understand the clinical context in which the research which s/he is to undertake is placed. The remainder of the time (at least 75%) will be spent in a defined tutorial research program with a preceptor in one of the laboratories or clinical investigation areas described in this grant proposal. Trainees pursuing basic research will be laboratory-based and will supplement their research training with graduate coursework as identified in each research track. Trainees in areas of clinical investigation will be encouraged to pursue a masters in health sciences in clinical research degree granted by the Duke University Clinical Research Training Program; at a minimum, they will be expected to complete an introductory course in statistics and other coursework pertinent to clinical investigation. The training program funded by this award will be offered to qualified persons holding either the M.D. and/or Ph.D. degree with interest in research training in transfusion medicine and hematology. The trainees in all tracks will also take part in an inter- and intradepartmental didactic program, including both standardized curricular content as well as topical seminars and conferences. Semiannual assessments by a Research Oversight Committee will include: oral and written presentations of research progress by the trainee, preparation of manuscripts, career development activities, and submission of grant proposals. We will endeavor to include at least one PhD trainee each year. Persons from minority groups and women will be encouraged to enter the program. The facilities for research training will be based at the various research laboratories and clinics of Duke University and the allied Veterans' Administration Medical Centers in Durham, North Carolina. Fulfillment of the training goals of this program will meet present and future needs for scientists and physician-scientists who can conduct high caliber research in both basic and clinical sciences related to transfusion medicine and hematology and who can translate the rapidly growing knowledge in these fields to improvements in the care of patients with hematologic disorders and other conditions requiring blood product and stem cell therapy.

Public Health Relevance

This training program will provide basic; translational and clinical research training to physicians and PhDscientists focused on problems related to hematologic diseases and their treatment; including the science oftransfusion; cellular therapy; and hematopoietic stem cell transplantation. Advances in these fields are neededin order to improve the health of millions of people with inherited and acquired blood disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
3T32HL007057-41S1
Application #
9486253
Study Section
Program Officer
Chang, Henry
Project Start
1975-07-01
Project End
2021-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
41
Fiscal Year
2017
Total Cost
$5,607
Indirect Cost
$415
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Wild, Daniel; Sung, Anthony D; Cardona, Diana et al. (2016) The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review. Dig Dis Sci 61:806-13
Lykken, Jacquelyn M; Horikawa, Mayuka; Minard-Colin, Veronique et al. (2016) Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. Blood 127:1886-95
Sung, Anthony D; Sung, Julia A M; Thomas, Samantha et al. (2016) Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. Clin Infect Dis 63:999-1006
Papalas, John A; McKinney, Matthew S; Kulbacki, Evan et al. (2014) Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma. Am J Dermatopathol 36:148-52
Bennett-Guerrero, Elliott; Kirby, Brett S; Zhu, Hongmei et al. (2014) Randomized study of washing 40- to 42-day-stored red blood cells. Transfusion 54:2544-52
Kirby, Brett S; Hanna, Gabi; Hendargo, Hansford C et al. (2014) Restoration of intracellular ATP production in banked red blood cells improves inducible ATP export and suppresses RBC-endothelial adhesion. Am J Physiol Heart Circ Physiol 307:H1737-44
Patel, Sachit A; Coulter, Don W; Grovas, Alfred C et al. (2014) Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol 36:491-4
Sung, Anthony D; Chao, Nelson J (2013) Acute graft-versus-host disease: are we close to bringing the bench to the bedside? Best Pract Res Clin Haematol 26:285-92
Lee, Grace M; Arepally, Gowthami M (2013) Diagnosis and management of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 27:541-63
Brander, Danielle; Rizzieri, David; Gockerman, Jon et al. (2013) Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. Leuk Lymphoma 54:2627-30

Showing the most recent 10 out of 49 publications